Bayer Focusing On Early CKD Testing In Kerendia US Launch
Less Than 50% Of Doctors Use UACR For Earlier Diagnosis
The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.
